MISSISSAUGA, ON, April 19, 2012 /PRNewswire/ - Covalon
Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an
advanced medical technologies company, today announced it is
presenting its newest line of advanced wound care products from
April 19th to 22nd at the Spring
Symposium on Advanced Wound Care ("Spring SAWC") in Atlanta, GA. Covalon's new wound care
products include:
- SurgiClearTM antimicrobial clear silicone adhesive
film dressing,
- CovaStatTM fast-acting haemostatic wound
dressing,
- CovaSorbTM bioactive foam replacement wound
dressing, and
- CovaGenTM negative pressure friendly biologically
active wound contact layer dressing.
These exciting new products will be available
for license or distribution, following regulatory clearance.
Covalon's ColActive® Plus Ag collagen wound dressing for treatment
of chronic wounds and diabetic foot ulcers has been marketed and
sold in the United States and
elsewhere since 2005.
Now in its 25th year, Spring SAWC is the largest
annual gathering of wound care clinicians in the United States. The symposium
provides an opportunity for Covalon to showcase its new wound care
products to more than 2,000 physicians, podiatrists, nurses,
therapists, and researchers and over 200 leading wound care product
manufacturers, wholesalers and distributors are expected to attend
the 2012 Spring SAWC meeting.
"Our team is extremely excited to present our
newest advanced wound care products at this year's Spring SAWC
meeting," said Brian Pedlar,
Covalon's Chief Executive Officer. "We are looking forward to
introducing our new line-up of products to our growing domestic and
international distribution channels and to medical product
companies who are looking to license breakthrough new
products."
To learn more about Covalon's products and
services, please visit us at booth 134 in the Georgia World
Congress Center from April 19th to
22nd or contact Brian Pedlar,
CEO, Covalon Technologies Ltd. at bpedlar@covalon.com.
About Covalon
Covalon Technologies Ltd. researches, develops
and commercializes new healthcare technologies that help save lives
around the world. Covalon's patented technologies, products and
services address the advanced healthcare needs of medical device
companies, healthcare providers and individual consumers. Covalon's
technologies are used to prevent, detect and manage medical
conditions in specialty areas such as wound care, tissue repair,
infection control, disease management, medical device coatings and
biocompatibility. To learn more about Covalon, visit our website at
www.covalon.com
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
This news release contains forward-looking
statements which reflect the Company's current expectations
regarding future events. The forward-looking statements are often,
but not always, identified by the use of words such as "seek",
"anticipate", "plan, "estimate", "expect", "intend" and statements
that an event or result "may", "will", "should", "could" or "might"
occur or be achieved and other similar expressions. These
forward-looking statements involve risk and uncertainties,
including the difficulty in predicting product approvals,
acceptance of and demands for new products, the impact of the
products and pricing strategies of competitors, delays in
developing and launching new products, the regulatory environment,
fluctuations in operating results and other risks, any of which
could cause results, performance, or achievements to differ
materially from the results discussed or implied in the
forward-looking statements. Many risks are inherent in the
industry; others are more specific to the Company. Investors should
consult the Company's ongoing quarterly filings for additional
information on risks and uncertainties relating to these
forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements
whether as a result of new information, further events or
otherwise.
SOURCE Covalon Technologies Ltd.